Fresenius Kabi has reached a milestone on the road to approval for another biosimilar. MSB11455, a biosimilar candidate for Neulasta® (pegfilgrastim), has met its primary endpoints in the two pivotal clinical studies. For more information please see the website of Fresenius Kabi.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, supports the recommendation by the United Kingdom’s National Institute for Health and Care Excellence (NICE) to facilitate population healthcare management for UK patients with end-stage renal disease. In a guideline on renal replacement therapy published on October 3, 2018, NICE, a non-departmental public body of the UK’s Department of Health, advises health and social care professionals to consider hemodiafiltration (HDF) rather than high-flux hemodialysis (HD) if the patient is treated in-center, due to the positive impact on patient outcomes and cost-effectiveness.
High-flux HD is the application of high-flux dialyzers to remove a broad spectrum of small and large uremic toxins in order to contribute towards better management of dialysis patients. HDF adds a convective component to the high-flux HD treatment, making it even more effective in removing larger toxins and further improving patient outcomes.
In order to provide evidence-based guidance, NICE systematically reviewed best available renal replacement therapy studies and conducted an economic evaluation. The assessment identified clear benefits of HDF treatment for both renal disease patients and the national healthcare system, as HDF is not only considered cost-effective but is also expected to decrease mortality rates among patients.
Fresenius Medical Care has a long-standing commitment to make HDF available to patients to achieve the best possible outcomes. The company has developed innovative technologies which automatically maximize substitution rates in HDF and support the application of HighVolumeHDF®. This makes HDF treatments as simple as HD, and allows HDF treatments to be delivered at the same cost as HD in the UK.
Dr. Katarzyna Mazur-Hofsaess, Chief Executive Officer of Fresenius Medical Care for Europe, the Middle East and Africa, said: “The NICE guidelines incorporate the existing evidence base for the benefits of HDF therapy. We are convinced that our HighVolumeHDF® therapy platform provides the easiest way for the user to deliver HDF to patients. Our commitment to make HighVolumeHDF® available to all patients across the UK remains a top priority for us.”
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
In the lawsuit by Akorn, Inc. against Fresenius for the consummation of the April 2017 merger agreement the Court of Chancery in the U.S. state of Delaware today ruled in favor of Fresenius. The judgment is not yet final.
Fresenius terminated the merger agreement due to Akorn’s failure to fulfill several closing conditions. An independent investigation initiated by Fresenius had revealed, among other things, material breaches of FDA data integrity requirements relating to Akorn's operations. Akorn responded by suing in the Court of Chancery in Delaware for the consummation of the agreement.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
May 17, 2019 - 10:00 am - 00:00 am
Frankfurt, Germany
Annual General Meeting 2019, Fresenius
Webcast (Replay) of the speech of CEO Stephan Sturm
WebcastInformation and documents
The price increase for hospital services in Germany has been set at 2.65% for 2019. This is in line with the level of past years.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, has been recognized for the 10th consecutive year as a sustainability leader with inclusion in the Dow Jones Sustainability Index (DJSI Europe). The DJSI Europe index represents the top 20 percent of the largest 600 European companies in the S&P Global BMI, based on the international investment company RobecoSAM’s analysis of their economic, environmental and social performance.
This year, Fresenius Medical Care scored particularly highly for its reporting on environmental and social issues as well as its materiality analysis, which identifies issues in the economy, environment and society that may significantly affect a company’s performance. With publication of its first non-financial group report in 2018, Fresenius Medical Care has also established a global sustainability governance structure. This will further improve the coordination and management of sustainability topics across all regions.
Rice Powell, Chief Executive Officer of Fresenius Medical Care and head of the company’s Sustainability Decision Board, said: “Over the past years, we have continuously built up our sustainability efforts, as we are convinced that acting in a responsible and sustainable manner goes hand in hand with our commercial success. Being included in the renowned Dow Jones Sustainability Index for 10 years in a row makes us proud, and confirms that we are on the right track by putting patients first.”
Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, is opening a new hospital in Cordoba today. The company now has six hospitals in Andalusia, Spain’s most southernly autonomous community. The six-floor, approximately 25,000-square-meter (269,000-square-foot) facility includes 100 large private patient rooms, a 24-hour emergency department, seven operating rooms and a surgical outpatient clinic. Quirónsalud has invested €50 million in the new hospital.